Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Net Margin (2016 - 2025)

Historic Net Margin for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to 42.36%.

  • United Therapeutics' Net Margin rose 10900.0% to 42.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 53.33%, marking a year-over-year increase of 14800.0%. This contributed to the annual value of 41.53% for FY2024, which is 7800.0% down from last year.
  • According to the latest figures from Q3 2025, United Therapeutics' Net Margin is 42.36%, which was up 10900.0% from 38.76% recorded in Q2 2025.
  • Over the past 5 years, United Therapeutics' Net Margin peaked at 21710.0% during Q4 2023, and registered a low of 3813.92% during Q4 2024.
  • Its 5-year average for Net Margin is 975.68%, with a median of 40.56% in 2025.
  • Its Net Margin has fluctuated over the past 5 years, first soared by 216831200bps in 2023, then crashed by -255239200bps in 2024.
  • United Therapeutics' Net Margin (Quarter) stood at 27.02% in 2021, then decreased by -1bps to 26.88% in 2022, then skyrocketed by 80676bps to 21710.0% in 2023, then tumbled by -118bps to 3813.92% in 2024, then soared by 101bps to 42.36% in 2025.
  • Its Net Margin was 42.36% in Q3 2025, compared to 38.76% in Q2 2025 and 40.56% in Q1 2025.